Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 251

1.

Postmenopausal hormone therapy and change in mammographic density.

Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G.

J Natl Cancer Inst. 2003 Jan 1;95(1):30-7.

PMID:
12509398
2.

Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.

Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, Bassett LW, Wasilauskas C, Bush T, Barrett-Connor E.

Ann Intern Med. 1999 Feb 16;130(4 Pt 1):262-9.

PMID:
10068383
3.
4.

Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.

McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, Wang CY, Brunner RL, Johnson KC, Manson JE, Lewis CE, Kotchen JM, Hulka BS; Women's Health Initiative Mammogram Density Study Investigators.

J Natl Cancer Inst. 2005 Sep 21;97(18):1366-76.

PMID:
16174858
5.

Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk.

Byrne C, Ursin G, Martin CF, Peck JD, Cole EB, Zeng D, Kim E, Yaffe MD, Boyd NF, Heiss G, McTiernan A, Chlebowski RT, Lane DS, Manson JE, Wactawski-Wende J, Pisano ED.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx001.

PMID:
28376149
6.

Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy.

Crandall CJ, Karlamangla A, Huang MH, Ursin G, Guan M, Greendale GA.

Arch Intern Med. 2006 Aug 14-28;166(15):1578-84. Erratum in: Arch Intern Med. 2006 Nov 13;166(20):2176.

PMID:
16908790
8.

Breast tenderness after initiation of conjugated equine estrogens and mammographic density change.

Crandall CJ, Aragaki AK, Cauley JA, McTiernan A, Manson JE, Anderson GL, Wactawski-Wende J, Chlebowski RT.

Breast Cancer Res Treat. 2012 Feb;131(3):969-79. doi: 10.1007/s10549-011-1803-9. Epub 2011 Oct 7.

10.

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.

Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH; Women's Health Initiative Memory Study.

JAMA. 2004 Jun 23;291(24):2947-58.

PMID:
15213206
11.

The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women.

Barrett-Connor E, Slone S, Greendale G, Kritz-Silverstein D, Espeland M, Johnson SR, Waclawiw M, Fineberg SE.

Maturitas. 1997 Jul;27(3):261-74.

PMID:
9288699
12.

Increases in serum estrone sulfate level are associated with increased mammographic density during menopausal hormone therapy.

Crandall CJ, Guan M, Laughlin GA, Ursin GA, Stanczyk FZ, Ingles SA, Barrett-Connor E, Greendale GA.

Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1674-81. doi: 10.1158/1055-9965.EPI-07-2779.

14.

Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial.

McTiernan A, Chlebowski RT, Martin C, Peck JD, Aragaki A, Pisano ED, Wang CY, Johnson KC, Manson JE, Wallace RB, Vitolins MZ, Heiss G.

J Clin Oncol. 2009 Dec 20;27(36):6135-43. doi: 10.1200/JCO.2008.21.7166. Epub 2009 Nov 9.

15.

Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens.

Lundström E, Wilczek B, von Palffy Z, Söderqvist G, von Schoultz B.

Climacteric. 2001 Mar;4(1):42-8.

PMID:
11379377
16.

Effects of estrogen with and without progestin on urinary incontinence.

Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, Aragaki A, Naughton MJ, Wallace RB, McNeeley SG.

JAMA. 2005 Feb 23;293(8):935-48.

PMID:
15728164
17.

Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.

Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT; WHI Investigators.

JAMA. 2006 Apr 12;295(14):1647-57.

PMID:
16609086
18.

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.

Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB.

JAMA. 2013 Oct 2;310(13):1353-68. doi: 10.1001/jama.2013.278040.

19.

Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.

Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey M, Freeman R, Hays J; Women's Health Initiative Memory Study.

JAMA. 2004 Jun 23;291(24):2959-68.

PMID:
15213207
20.

A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.

Baracat EC, Barbosa IC, Giordano MG, Haidar MA, Marinho RM, Menegocci JC, Morais KM, Tomaz G, Wehba S.

Climacteric. 2002 Mar;5(1):60-9. Erratum in: Climacteric 2002 Jun;5(2):vi.

PMID:
11974560

Supplemental Content

Support Center